Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella

Phase 1

Completed

• Conditions: Shigellosis
• Interventions: Biological: Shigella vaccine

• Registration Number: NCT01069471
• Lead Sponsor: GlycoVaxyn AG

Brief Summary

Healthy volunteers will receive a 2-dose vaccination with Shigella dysenteriae candidate vaccine spaced 8 weeks apart. The objective is to demonstrate the safety and reactogenicity of the Shigella dysenteriae bioconjugate vaccine (GVXN SD133) alone or in combination with an adjuvant (Aluminium Hydroxide). The safety and reactogenicity of the GVXN SD133 vaccine will be also evaluated at two different concentrations of antigen, Shigella polysaccharide O1. Blood samples will be collected at intervals to examine systemic vaccine antigen-specific immune responses.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-02
• Study First Submitted: 2010-02-15
• Study First Submitted QC: 2010-02-16
• Study First Posted: 2010-02-17
• Status Verified: 2010-10
• Primary Completion: 2010-10
• Study Completion: 2010-10
• Last Update Submitted: 2010-10-11
• Last Update Posted: 2010-10-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Subjects of both sexes, aged between 18 and 50 years.
• Subjects who have undergone a detailed medical history, clinical checkup and are in good health.
• Subjects who have understood the purpose of the study and have freely signed the informed consent.
• Subjects who consent with repeated blood samples taking.
• Subjects who will be available to perform the follow-up visits, are reachable by telephone, and are able to complete the diary cards throughout the study duration.
• For female volunteers, a negative pregnancy test and an adequate contraception throughout the study duration.

Exclusion Criteria

• Known history of recent contact Shigella infection or long-term residence in a Shigella endemic region (Central America, Africa, and India).
• Known history of hypersensitivity to any component of the vaccine (EPA; Aluminium Hydroxide).
• Subjects with compromised immune system.
• Family history of congenital or hereditary immunodeficiency.
• Chronic administration of an immunosuppressive treatment or other immune-modifying drugs within six months prior to the first vaccine dose.
• Subjects that received any other vaccine during the 1 month preceding the 1st injection and may receive before the 2nd injection. If the subject needs to be vaccinated during this period, he/she will be withdrawn from the study.
• Subjects suffering of a disease at the time of enrolment. 'Disease' is defined as the presence of a mild or severe illness with or without fever.
• Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.
• Any laboratory data collected during the screening phase found to be outside the normal range defined by the laboratory.
• Positive test for HIV, and evidence of HBV or HCV.
• Pregnant or breast-feeding women.
• History of alcohol, drug or psychotropic drug abuse (which interferes with a normal lifestyle) during the previous year.
• Subjects for which follow-up is compromised due to socio-cultural, geographic or psychological reasons.
• Any other significant finding that in the opinion of the Investigator that would increase the risk of having an adverse outcome from participating in the study.
• Subjects that are participating or have participated in another clinical trial in the last 6 months.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
HHD O1-EPA plus adjuvant	Shigella vaccine	10 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA adjuvanted to aluminium hydroxide
HHD O1-EPA	Shigella vaccine	10 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA
LHD O1-EPA adjuvanted	Shigella vaccine	2 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA adjuvanted to aluminium hydroxide
LHD O1-EPA	Shigella vaccine	2 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA

Primary Outcome Measures

Name	Time	Method
Safety and reactogenicity of the bioconjugate vaccine, GVXN SD133	Each study visits and at the and of the study

Secondary Outcome Measures

Name	Time	Method
Humoral immunogenicity	at day 0, 30, 60, 90 and 150

Trial Locations

Locations (1)

Institute of Social and Preventive Medicine; 🇨🇭 Zurich, Switzerland